全基因组荟萃分析识别非肌层浸润性膀胱癌复发与进展相关新基因
该研究对来自荷兰、英国、加拿大和西班牙的3400例新诊断非肌层浸润性膀胱癌患者进行全基因组关联分析及荟萃分析,旨在识别与无复发生存和无进展生存相关的单核苷酸多态性。结果发现14号染色体上与无复发生存显著相关的位点(lead SNP rs12885353),并鉴定出多个候选基因,其中SCFD1高表达与无复发生存改善相关。
要点
- 14号染色体rs12885353与NMIBC无复发生存显著相关(HR 1.55)。
- SCFD1高表达与无复发生存改善相关(HR 0.70)。
- IFT140、UBE2I、FAHD1和NME3与无进展生存方向一致。
核心结论
- 这是首个NMIBC预后全基因组关联研究,识别出多个与复发或进展相关的新候选位点和五个基因。
研究设计与样本
- 研究纳入3400例来自荷兰、英国、加拿大和西班牙的新诊断NMIBC患者,使用Illumina OmniExpress和Infinium Global Screening Array芯片结合基因型填充生成全基因组胚系SNP数据。
- 对无复发生存和无进展生存分别进行队列特异性GWAS,采用Cox比例风险模型,结果通过固定效应逆方差加权荟萃分析合并。
主要发现
- 荟萃分析发现14号染色体上与无复发生存全基因组显著相关的位点(lead SNP rs12885353,C vs T等位基因HR 1.55,95%CI 1.33-1.82,p=4.0×10-8),包含G2E3和SCFD1基因。
- SCFD1高表达与无复发生存改善相关(HR 0.70,95%CI 0.59-0.84,pFDR=0.003)。
- 另有12个位点与无复发生存提示性相关(p<10-5),指向18个额外候选基因;无进展生存有10个位点显示提示性关联,指示36个候选基因。
- 其中10个基因的表达水平与无进展生存显著相关,IFT140、UBE2I、FAHD1和NME3四个基因的方向与荟萃分析结果及已发表文献一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) is characterized by frequent recurrences and a risk of progression in stage and grade. Increased knowledge of underlying biological mechanisms is needed. OBJECTIVE: To identify single nucleotide polymorphisms (SNPs) associated with recurrence-free (RFS) and progression-free (PFS) survival in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: We analyzed outcome data from 3400 newly diagnosed NMIBC patients from the Netherlands, the UK, Canada, and Spain. We generated genome-wide germline SNP data using Illumina OmniExpress and Infinium Global Screening Array in combination with genotype imputation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cohort-specific genome-wide association studies (GWASs) for RFS and PFS were performed using a Cox proportional hazard model. Results were combined in a fixed-effect inverse-variance weighted meta-analysis. Candidate genes for the identified SNP associations were prioritized using functional annotation, gene-based analysis, expression quantitative trait locus analysis, and transcription factor binding site databases. Tumor expression levels of prioritized genes were tested for association with RFS and PFS in an independent NMIBC cohort. RESULTS AND LIMITATIONS: This meta-analysis revealed a genome-wide significant locus for RFS on chromosome 14 (lead SNP rs12885353, hazard ratio [HR] C vs T allele 1.55, 95% confidence interval [CI] 1.33-1.82, p = 4.0 × 10-8), containing genes G2E3 and SCFD1. Higher expression of SCFD1 was associated with increased RFS (HR 0.70, 95% CI 0.59-0.84, pFDR = 0.003). Twelve other loci were suggestively associated with RFS (p < 10-5), pointing toward 18 additional candidate genes. For PFS, ten loci showed suggestive evidence of association, indicating 36 candidate genes. Expression levels of ten of these genes were statistically significantly associated with PFS, of which four (IFT140, UBE2I, FAHD1, and NME3) showed directional consistency with our meta-analysis results and published literature. CONCLUSIONS: In this first prognostic GWAS in NMIBC, we identified several novel candidate loci and five genes that showed convincing associations with recurrence or progression. PATIENT SUMMARY: In this study, we searched for inherited DNA changes that affect the outcome of non-muscle-invasive bladder cancer (NMIBC). We identified several genes that are associated with disease recurrence and progression. The roles and mechanisms of these genes in NMIBC prognosis should be investigated in future studies.
引用
- Galesloot TE, Grotenhuis AJ, Kolev D, et al. Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2021. PMID: 34353775. doi:10.1016/j.euo.2021.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。